Ola Fjellström

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index1.2kcitations59works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(10), ATP Synthase and ATPases Research(10), Liver Disease Diagnosis and Treatment(6), Blood Coagulation and Thrombosis Mechanisms(6), Enzyme Structure and Function(6)

Publications59 total

The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans
Molecular Therapy Advances·2026
Inhibition of Nicotinamide N-Methyltransferase (NNMT), Linked to Progression of Human CKD, Blocks Kidney Injury in a Mouse Model of Diabetic Kidney Disease
Journal of the American Society of Nephrology·2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
Journal of Hepatology·2025· 32 cited
LBP-031 AZD2693, a potent PNPLA3 antisense oligonucleotide, decreases hepatic PNPLA3 mRNA and liver fat content in participants with presumed MASH and homozygous for the PNPLA3148M risk allele
Journal of Hepatology·2024
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo‐Controlled Study
Journal of the American Heart Association·2024· 3 citedOpen Access
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure
Journal of Medicinal Chemistry·2024· 20 cited
Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction
European Heart Journal·2024· 8 citedOpen Access
The greater impact of <scp><i>PNPLA3</i></scp> polymorphism on liver‐related events in Japanese non‐alcoholic fatty liver disease patients: A multicentre cohort study
Liver International·2023· 30 citedOpen Access
Impact of PNPLA3 polymorphism on non-alcoholic fatty liver disease in Japan: a multicenter cohort study
Journal of Hepatology·2023
Patatin-like phospholipase domain-containing 3 (PNPLA3) risk allele increases rate of progression to end-stage liver disease outcomes and decreases survival rate over time irrespective of degree of fibrosis
Journal of Hepatology·2023· 1 cited
Abstract 13097: Safety, Pharmacokinetics, and Pharmacodynamics of AZD3366 Alone and in Combination With Aspirin and Ticagrelor in Healthy Subjects
Circulation·2022· 1 cited
Administration of a human recombinant apyrase (AZD3366) limits myocardial tissue injury and improves cardiac function in a pig model of STEMI assessed by serial CMR
European Heart Journal·2022· 2 citedOpen Access
Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans
Hepatology Communications·2022· 21 citedOpen Access
Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury
Cardiovascular Drugs and Therapy·2022· 6 cited
Administration of a soluble ADPase, AZD3366, on top of ticagrelor confers additional cardioprotective benefits to that of ticagrelor alone
European Heart Journal·2020
Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function
Journal of Biological Chemistry·2020· 13 citedOpen Access
Identification of novel GPR81 agonist lead series for target biology evaluation
Bioorganic & Medicinal Chemistry Letters·2020· 11 citedOpen Access
Abstract 11146: AZD3366-an Optimized Recombinant Human Apyrase Combining Anti Platelet, Anti Inflammatory and Tissue Protective Actions With Low Bleeding Risk for Potential Mitigation of Thromboembolic Complications
Circulation·2019· 1 cited
Small molecule modulators of PCSK9 – A literature and patent overview
Bioorganic & Medicinal Chemistry Letters·2018· 24 citedOpen Access
Overexpressing cell systems are a competitive option to primary adipocytes when predicting in vivo potency of dual GPR81/GPR109A agonists
European Journal of Pharmaceutical Sciences·2017· 6 cited
page 1 of 3Next →

Frequent Co-authors

Jan Rydström(11), Carina Johansson(8), David Gustafsson(6), Tania Bizouarn(6), Johan Meuller(4), Ingemar Nilsson(4), Stephen Hanessian(4), Daniel Hovdal(4), Xiang Hu(4), Carl Whatling(4), Jonas Boström(3), Magnus Axelsson(3), Anders Bergkvist(3), Göran Karlsson(3), Wolfgang Knecht(3), Viveca Nerme(3), Jenny Sandmark(3), Anna Tigerström(3), Yafeng Xue(3), Johan Ulander(3)